Notes to reconciliations of equity as of 31 March 2013 A Property, plant and equipment B Goodwill C Other intangible assets D Investments in associates and joint ventures E Deferred tax assets F Other financial assets (non-current) G Other non-current assets H Inventories The major components of the reconciliations of equity as of 31  March 2013 are as follows: Under Japanese GAAP, “Buildings and structures, net”,  “Machinery, equipment and vehicles, net”, “Tools, furniture and  fixtures, net”, “Land”, and “Construction in progress” were  presented separately, whereas they have been presented  together as “Property, plant and equipment” under IFRS. Under Japanese GAAP, assets held for sale were included in  “Property, plant and equipment, net”, whereas they are pre- sented separately as “Assets held for sale” in accordance  with IFRS. The amount of “Property, plant and equipment” has decreased  as a result of revisions to the depreciation method and useful  lives and using the fair value as deemed cost for certain items  of property, plant and equipment upon the adoption of IFRS. (Presentation) (Recognition and measurement) (Recognition and measurement) (Presentation) “Patents” presented separately under Japanese GAAP have  been included in “Other intangible assets” under IFRS. (Recognition and measurement) Under Japanese GAAP, costs associated with the in-licensing of  products and technologies incurred before filing an application  for approval from regulatory authorities were recognised as  research and development expenses, but under IFRS, those  costs that satisfy certain criteria are capitalised as intangible  assets and amortised over their estimated useful lives on a  straight-line basis. Also, the Group revised the useful lives of  certain marketing rights upon adoption of IFRS. As a result of  those factors, “Other intangible assets” has increased by  ¥141,670 million. Investments in associates and joint ventures included in “Other”  comprising investments and other assets under Japanese  GAAP have been presented separately as “Investments in  associates and joint ventures” under IFRS. “Merchandise and finished goods”, “Work in progress” and  “Raw materials and supplies”, which were presented sepa- rately under Japanese GAAP, are presented together as  “Inventories” under IFRS. Investments in associates and joint ventures included in  “Other” comprising investments and other assets under  Japanese GAAP have been presented separately as “Investments in associates and joint ventures” under IFRS. Security deposits and other investments included in “Other”  comprising investments and other assets under Japanese  GAAP have been included in “Other financial assets” (non-current) under IFRS. “Investment securities” presented separately under Japanese  GAAP have been included in “Other financial assets” (non-current) under IFRS. Deferred tax assets presented separately as current and  non-current under Japanese GAAP have been reclassified as  non-current assets under IFRS. Under Japanese GAAP, the tax effect associated with the  elimination of an unrealised gain or loss was calculated using  the effective tax rate of the seller, while under IFRS, it is  calculated using the effective tax rate of the purchaser. In addition, deferred tax assets are recognised on the  temporary differences resulting from the reconciliations to IFRS. Security deposits and other investments included in  “Other” comprising investments and other assets under  Japanese GAAP have been included in “Other financial assets”  (non-current) under IFRS. Under Japanese GAAP, unquoted equity shares are stated at  cost calculated mainly by using the moving average method.  However, under IFRS, unquoted equity shares are measured at  fair value. As a result, there has been an increase of ¥9,736  million in “Other financial assets” (non-current). Under Japanese GAAP, goodwill was amortised over a speci- fied period, while under IFRS, goodwill is not amortised. As a  result, the amount of “Goodwill” has increased. (Presentation) (Recognition and measurement) (Presentation) (Recognition and measurement) (Presentation) (Presentation) (Presentation) Financial Section Annual Report 2014 _  Astellas Pharma Inc.  161